Romosozumab
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Romosozumab
- Romosozumab: From Postmenopausal Osteoporosis to Osteoporosis Management in Patients with Chronic Kidney Disease
Romosozumab: From Postmenopausal Osteoporosis to Osteoporosis Management in Patients with Chronic Kidney Disease
One-Sentence Summary
Romosozumab is a sclerostin-inhibiting monoclonal antibody whose established use, based on the FRAME/ARCH trial evidence embedded in this Evidence Pack, is postmenopausal osteoporosis. Among the 10 candidate indications TxGNN generated for this drug, the strongest evidence-backed signal is safe and effective use in osteoporosis patients with concurrent chronic kidney disease (CKD) (“impaired renal function disease”), supported by 1 clinical trial and 15 publications, including two independent Phase 3 subgroup analyses and a cross-CKD-stage meta-analysis. Note: this Evidence Pack contains 10 ranked candidates in total; 7 of them remain at TxGNN-score-only (L5/Hold) level and are summarized separately below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Postmenopausal osteoporosis (inferred from FRAME/ARCH trial context cited throughout this pack’s rationale; no independent EU/TW license record available) |
| Predicted New Indication | Osteoporosis management in patients with impaired renal function / CKD |
| TxGNN Prediction Score | 91.50% |
| Evidence Level | L2 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, a fully sourced mechanism-of-action record is not available (original_moa is flagged as a data gap, severity High, DG002). Based on information embedded in the evidence pack’s own rationale fields, romosozumab is a monoclonal antibody that inhibits sclerostin, thereby de-repressing Wnt/β-catenin signalling and promoting bone formation — the mechanism underlying its proven efficacy in postmenopausal osteoporosis in the pivotal FRAME and ARCH Phase 3 trials.
Chronic kidney disease independently raises fracture risk and is characterized by elevated circulating sclerostin as part of CKD-Mineral and Bone Disorder (CKD-MBD). This creates a direct mechanistic rationale for anti-sclerostin therapy in this population, rather than a purely coincidental knowledge-graph association.
Critically, this candidate is not solely a mechanistic hypothesis: post-hoc subgroup analyses of both FRAME and ARCH (including a dedicated Japanese cohort) directly evaluated efficacy and safety in patients with mild-to-moderate CKD, a Phase 1 study (NCT01833754) directly characterized pharmacokinetics in stage 4 and dialysis-dependent stage 5 renal impairment, and an independent meta-analysis compared anti-osteoporotic agents across CKD stages. This combination of population-specific Phase 3 subgroup data, a dedicated PK trial, and meta-analytic confirmation is why this candidate reaches L2/”Proceed with Guardrails,” the highest evidence tier among all 10 candidates in this pack.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01833754 | Phase 1 | Completed | 24 | Single 210 mg SC dose in healthy subjects vs. stage 4 or hemodialysis-dependent stage 5 renal impairment; evaluated safety, tolerability and immunogenicity. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35466448 | 2022 | RCT (subgroup) | J Bone Miner Res | Post-hoc analysis of FRAME and ARCH (Phase 3 RCTs): efficacy and safety of romosozumab in postmenopausal women with osteoporosis and mild-to-moderate CKD |
| 38972312 | 2024 | Meta-analysis of RCTs | Kidney Blood Press Res | Comparative efficacy/safety of anti-osteoporotic agents across CKD stages, including stages 4-5 |
| 35639174 | 2022 | RCT (subgroup, Japanese cohort) | J Bone Miner Metab | Post-hoc FRAME analysis in Japanese postmenopausal women with osteoporosis and CKD |
| 35304747 | 2022 | Phase 1 PK/PD study | J Clin Pharmacol | Single-dose PK/PD/safety in severe renal impairment and hemodialysis-dependent ESRD: exposure 31–43% higher than normal renal function |
| 34231877 | 2021 | Cochrane Systematic Review | Cochrane Database Syst Rev | Pharmacological interventions vs. placebo/no treatment for osteoporosis in CKD stages 3-5D |
| 40669844 | 2025 | Meta-analysis/Review | Renal Failure | Adynamic bone disorder in CKD; biomarkers for diagnosis and therapeutic targets |
| 41171457 | 2026 | Narrative Review | Osteoporos Int | Efficacy and safety of romosozumab in patients with CKD and osteoporosis |
| 40457078 | 2025 | Review | Curr Osteoporos Rep | Treatment of osteoporosis in patients with chronic kidney disease |
| 40377654 | 2025 | Review | Curr Opin Nephrol Hypertens | Agents to treat osteoporosis in chronic kidney disease |
| 36330828 | 2023 | RCT subgroup (CV safety) | J Bone Miner Res | Cardiovascular safety of romosozumab in postmenopausal women with CKD |
Other Candidate Indications in This Evidence Pack
This is a multi-candidate Evidence Pack; the 10 TxGNN-ranked candidates vary widely in evidence quality. For transparency, the remaining 9 are summarized here rather than treated as separate reports:
| Rank | Disease | Score | Evidence Level | Decision Stage | Recommendation | Note |
|---|---|---|---|---|---|---|
| 1 | Obsolete vitamin D deficiency | 97.83% | L5 | S0 | Hold | Obsolete ontology term; likely knowledge-graph node artifact, not a biological signal |
| 2 | Calcium-alkali syndrome | 97.44% | L5 | S0 | Hold | Reflects a calcium/vitamin D toxicity risk, not a therapeutic use |
| 3 | Primary bone dysplasia with defective mineralization | 97.27% | L5 | S0 | Hold | Mechanistically plausible (Wnt/sclerostin) but zero trial/literature support |
| 4 | Severe nonproliferative diabetic retinopathy | 95.01% | L5 | S0 | Hold | No direct mechanistic or evidentiary link; likely embedding-space false positive |
| 5 | Renal osteodystrophy | 94.28% | L4 | S1 | Research Question | 9 reviews + 2 case reports; strong mechanistic rationale (elevated sclerostin in CKD-MBD), but zero trials with this as primary endpoint |
| 6 | Osteomalacia | 93.47% | L4 | S0 | Hold | Only 2 papers, neither directly evaluates romosozumab for this condition |
| 7 | Pregnancy- and lactation-associated osteoporosis | 92.86% | L4 | S1 | Research Question | Same core indication (osteoporosis) in a special population; 3 independent case reports of successful off-label use, no RCT |
| 8 | Autosomal dominant neovascular inflammatory vitreoretinopathy | 92.43% | L5 | S0 | Hold | Indirect LRP5/Wnt link only; rare ophthalmic disease, no evidence |
| 9 | Worth syndrome | 92.37% | L5 | S0 | Hold | LRP5 gain-of-function (high bone mass) — mechanistically opposite to romosozumab’s action; likely false positive, potential theoretical contraindication |
| 10 | Impaired renal function disease | 91.50% | L2 | S2 | Proceed with Guardrails | Featured candidate above — strongest evidence tier in this pack |
Rank 7 (pregnancy/lactation-associated osteoporosis) is worth monitoring as a secondary research question given consistent positive case-report signals, but requires clarification of reproductive/lactation safety before any further evaluation.
EU Market Information
Romosozumab currently shows no EU marketing authorization records in this Evidence Pack (total_licenses: 0, market_status: Not marketed). No product/authorization table can be generated from this data source.
Safety Considerations
- Data Gap (Blocking): Label warnings and contraindications for romosozumab (
safety.key_warnings,safety.contraindications) have not yet been retrieved from an authoritative source (SmPC/label PDF). This is flagged in the pack as a Blocking gap (DG001) — it currently prevents this candidate from completing the S1 safety pre-screen. - Drug Interaction Data: No DDI query results are available (
query_status: not_found). - Signal worth tracking: Two literature items independently focused on cardiovascular safety of romosozumab in CKD populations (PMID 36330828, and PMID 34822428 cited under the renal osteodystrophy candidate) — this suggests cardiovascular risk monitoring should be a specific focus if this indication is pursued further, consistent with romosozumab’s known class-level cardiovascular signal.
Please refer to the SmPC for complete safety information once available.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Among 10 TxGNN candidates for romosozumab, only the “impaired renal function disease” candidate (osteoporosis treatment in patients with concurrent CKD) is backed by population-specific Phase 3 subgroup data (FRAME/ARCH, including a Japanese cohort), a dedicated Phase 1 PK/PD trial in stage 4/hemodialysis-dependent renal impairment, and a cross-CKD-stage meta-analysis — reaching L2 evidence with no dose-adjustment signal identified. This is sufficient to proceed cautiously, but not to a full “Go,” since no trial has used a CKD-MBD/renal osteodystrophy outcome as its primary endpoint.
To proceed, the following is needed:
- Retrieve SmPC/label warnings and contraindications (Blocking gap DG001) — required before completing safety pre-screen
- Confirm formal mechanism-of-action documentation (gap DG002)
- Dedicated cardiovascular safety assessment for the CKD subpopulation, given the specific literature signal identified above
- Clarify EU/Taiwan regulatory pathway, since this pack shows zero current marketing authorizations for romosozumab in this jurisdiction
- If renal osteodystrophy (rank 5) or pregnancy/lactation-associated osteoporosis (rank 7) are to be pursued as distinct indications, both currently require a prospective study with disease-specific endpoints before advancing past “Research Question” stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.